Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Laboratorios Farmaceuticos Rovi, S.A.

Ratings ESG MSCI

Ratings ESG MSCI - Laboratorios Farmaceuticos Rovi, S.A.

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's enterprise value to sales, at 3.82 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.32B
BBB
1,051B
A
630B
BBB
489B
AAA
-
359B
AA
344B
AA
272B
AAA
246B
A
224B
BBB
187B
AA
Average 380.7B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. 0ILL Stock
  5. Ratings Laboratorios Farmaceuticos Rovi, S.A.